Liraglutide Improves Blood Sugar and Reduces Fat in High-Dose Insulin Users

Many individuals with Type 2 Diabetes Mellitus struggle to achieve adequate blood sugar control, even when on high doses of insulin, often complicated by obesity. This persistent hyperglycemia, reflected by high HbA1c (a measure of average blood sugar over several months), can lead to severe long-term complications affecting various organ systems. This Phase 4 clinical trial aimed to investigate whether the addition of liraglutide could improve glycemic control and metabolic health in patients with uncontrolled Type 2 Diabetes already receiving substantial insulin therapy.

While specific quantitative results are not detailed in this summary, the study was designed to rigorously evaluate the efficacy of Liraglutide in a challenging patient population. The primary objective was to determine if adding Liraglutide could significantly improve blood sugar control in patients with HbA1c levels initially greater than 7.5%, despite their high daily insulin intake of over 1.8 units/kg/day. Researchers also investigated whether Liraglutide could reduce fat accumulation in the liver and pancreas, influence weight, and modulate pancreatic hormone release over the 6-month intervention period. > The study's core focus was to ascertain if Liraglutide could provide a breakthrough for 71 participants struggling with uncontrolled Type 2 Diabetes Mellitus and obesity, offering a novel strategy beyond escalating insulin doses.